News
Novo Nordisk Faces $70B Blow as New CEO Steps In Amidst Weight-Loss Drug Turmoil
Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company faces increased competition in the obesity drug market and challenges from compounded versions of its weight-loss drugs,
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
July 29 - Novo Nordisk (NOVO?B) shares plunged about 20% Tuesday after the Danish drugmaker warned of weaker-than?expected ...
COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of ...
Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal ...
Here are some of the stories Wall Street is watching on Tuesday, July 29. Warren Buffett's Berkshire Hathaway (BRK-B, BRK-A) ...
European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...
Novo Nordisk (NVO) stock draws mixed views from Wall Street analysts after the obesity drugmaker cut its 2025 outlook for the ...
In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback